← All News
MarketWatch · 1 min read

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

This is a summary aggregated from MarketWatch. Read the complete article on the original site:

Read full article at MarketWatch

More Health & Medical News

This $250 watch is shockingly capable: Garmin Forerunner 70

Mashable · 28 min ago

Michigan Senate Democratic primary race remains too close to call as El-Sayed holds narrow lead – US politics live

The Guardian · 30 min ago

Private companies added just 44,000 workers in July, below expectations, ADP reports

CNBC · 44 min ago

U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech

NPR News · 1 hr ago

Michigan Democratic race to close to call with El-Sayed in narrow lead | First Thing

The Guardian · 1 hr ago

‘My head hit the driver’s window’: A teenager T-boned our car. Will Medicare pay my hospital bills?

MarketWatch · 1 hr ago